报价延迟最少15分钟:2026/10/23 04:55 EDT
盘前时段
|
||||
|
0.2235 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.2162
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.90/-0.27
|
|
企业价值
102.15M
|
| 资产负债 |
|
每股账面净值
1.02
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
10.33M
|
|
每股收益
0.24
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation.It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. |
